Four study updates from American College of Cardiology 2010 Scientific Sessions March 13-16, Atlanta, Georgia.

摘要

Adding fenofibrate to statin therapy and intensive blood pressure control, both failed to produce cardiovascular benefits for type 2 diabetics, report the two latest results from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) series of studies, presented in the late-breaking clinical trials I session. Both studies were published simultaneously online in the New England Journal of Medicine.These studies both show that we did not produce benefit above standard care (statin therapy and standard hypertensive therapy) for diabetics, which represents an important finding' said Henry Ginsberg, PI of the ACCORD lipid trial, from Columbia University (New York, NY). The investigators, he added, now need to look further at the smaller subgroups in each of the studies that showed trends towards benefit.